NAD to Lilly's Rival: 'Personalized' Isn't Made-to-Order

The short version: on November 4, 2026, the National Advertising Division (NAD) of BBB National Programs, the U.S. advertising self-regulation body, published its decision in a case brought by Eli Lilly against Good Life Meds, LLC, an online telehealth platform that markets compounded tirzepatide as 'Tirzepatide+'¹. NAD recommended discontinuing two families of claims: health benefits and personalization¹. For a clinician who prescribes or refers compounded tirzepatide, the case is a useful reminder of what product-level evidence can and cannot support.

What NAD decided about Tirzepatide+

Lilly, maker of Mounjaro and Zepbound (the FDA-approved tirzepatide products), challenged claims that compounded tirzepatide or 'Tirzepatide+' supports healthy weight loss, gives natural energy, improves blood sugar control and preserves lean muscle¹. NAD found those messages convey that the finished product, not just its ingredients individually, delivers those benefits¹.

Good Life submitted tirzepatide clinical literature, literature on the additive ingredients and real-world evidence, including a Gallup survey and retrospective cohort studies¹. NAD found it did not fit the claims for four reasons: the tirzepatide literature mostly concerned Lilly's approved products, nothing connected ingredient-level evidence to the compounded product, the survey and cohorts did not examine Tirzepatide+, and no evidence evaluated the safety of combining tirzepatide with the additives¹. FDA's decision to allow compounding during the shortage did not substantiate the claims either¹.

Why 'personalized' is not the same as made-to-order

Lilly also challenged phrases such as 'personalized medication', 'tailored to meet individual patient needs' and 'compounded for your unique needs'¹. NAD found these overstate the individualization involved: a prescriber may choose among formulations and doses and adjust treatment over time, but the product itself is not individually created for the patient¹. It recommended discontinuing 'personalized', 'custom formulated', 'tailored to meet individual patient needs' and 'compounded for your unique needs'¹.

The distinction matters because the regulatory framework rests on it. Under section 503A, FDA treats a compounded drug with the same active ingredient, a similar strength and the same route as a commercial product as 'essentially a copy'; that presumption does not apply if the prescriber determines and documents a change that produces a significant difference for an identified patient⁸⁹. FDA's example is that a compounded semaglutide plus vitamin B12 product may be treated as a copy if it is injectable and each ingredient is within 10% of the commercial strength⁸. One law-firm analysis notes FDA has not specified the type and amount of documentation a prescriber must create and maintain, and that the clarification 'does not have the force and effect of law'⁹.

FDA's September 18, 2026 warning letter to Empower Pharmacy went to exactly this point: orders lacking a prescriber statement of significant difference, rationales that appeared repeated word for word, and large volume¹⁰. We covered that case and Lilly's suits against aesthetic clinics in /pa/blog/fda-empower-warning-letter-glp1-essentially-copy/ and /pa/blog/retatrutida-demandas-lilly-clinicas-esteticas/.

What product-level evidence can and cannot support

The pivotal tirzepatide trials used Lilly's product. SURMOUNT-1 tested once-weekly tirzepatide in obesity¹³ and SURPASS-2 compared it with semaglutide in type 2 diabetes¹⁴; neither studied a compounded blend with additives. NAD's reasoning is basic evidentiary logic: efficacy shown for an approved product does not transfer automatically to a different formulation, and evidence for each additive alone does not show the combination is safe or effective¹.

On safety, the literature on compounded products is mostly surveillance. A poison-center case series documented administration errors with compounded semaglutide¹⁵, and poison-center data reviews describe changes in GLP-1 agonist exposures after demand surged¹⁶¹⁷. These papers do not prove every compounded product is unsafe, but they show why a safety message without data on the product itself is hard to defend. FDA states that compounded drugs are not approved by the agency¹².

• If you prescribe: document the clinical reason for any formulation or dose change for an identified patient, rather than leaning on the word 'personalized'⁸⁹.
• If you refer or recommend: ask the provider for the source behind each benefit claim and check that it concerns the product you are prescribing, not Mounjaro or Zepbound¹.
• If you communicate: NAD already received Lilly cases in June 2025 against sellers of compounded tirzepatide that discontinued their claims without a merits ruling³⁴.

A pattern of Lilly cases at NAD and in court

Good Life is not isolated. In June 2025, Hormone Fitness and Begin Anew MedSpa permanently discontinued claims about compounded tirzepatide during separate NAD inquiries brought by Lilly; NAD did not reach the merits and treated the discontinuance as if it had recommended it³⁴. The challenged claims included FDA approval³⁴ and, in Begin Anew's case, 'fast and extreme' weight loss without lifestyle changes and reduced nausea with B12⁴. Good Life differs because NAD did weigh the evidence and issued a decision on the merits¹.

In parallel, FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, and Commissioner Marty Makary said 'outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need'¹¹. FDA had declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025⁸; the first announcement that the tirzepatide shortage was over came in October 2024¹².

What comes next

An NAD decision is advertising self-regulation: it is not an FDA sanction or a court judgment. Even so, the message fits the direction of the FDA and the courts: the advantage of a compounded formulation has to be documented for an identified patient, and benefit claims need evidence about the specific product¹⁸¹⁰. This is journalism and regulatory analysis for health professionals, not a recommendation for use.